Effective polysaccharide(conjugate) vaccines against Neisseria meningitidis 
serogroups A, C, W, and Y have been widely used, but serogroup B meningococci 
remain a major cause of severe invasive meningococcal disease (IMD) worldwide, 
especially in infants. Recently, a vaccine, 4CMenB (Bexsero(®)), containing 
three recombinant proteins, and outer membrane vesicles (OMV) derived from a 
serogroup B meningococcal strain (MenB) has been licensed in Europe and 
Australia and is indicated for persons aged 2 mo or older. This article 
discusses what should be considered to enable a successful implementation of a 
broad coverage MenB vaccine in national immunization programs. Epidemiology 
data, vaccine characteristics including vaccine coverage, immunogenicity, 
post-implementation surveillance and costs are relevant aspects that should be 
taken into account when selecting an appropriate immunization strategy. The 
potential impact on strain variation and carriage, as well as monitoring vaccine 
effectiveness, and rare but potentially serious adverse events are points that 
need to be included in a post-implementation surveillance plan.